Lantern Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview
03/11/2023 11:29
* Lantern Pharma Inc LTRN.OQ LTRN.O is expected to show
no
change in quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Lantern Pharma Inc
is for
a loss of 45 cents per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lantern
Pharma
Inc is $20.5, above its last closing price of $2.74.
This summary was machine generated November 3 at 11:29 GMT. All
figures in US dollars unless otherwise stated
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview